POLBF
Poolbeg Pharma PLC·Healthcare
0.06
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.0452W H: $0.20
POLBF NEWS
proactiveinvestors.com
1d ago
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a...
proactiveinvestors.co.uk
2d ago
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a pre-investigational new drug meeting with the US Food and Drug Administration (FDA) for lead asset POLB 001. Cavendish reiterated its 'buy' rating and 19p target price, noting the FDA discussions de-risk the overall development programme by ensuring that the regulator agrees, at least in principle, that the data produced through the clinical programme could support approval.
proactiveinvestors.co.uk
2d ago
Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive feedback from the US Food and Drug Administration (FDA) in a pre-investigational new drug (IND) meeting for its lead asset POLB 001. POLB 001 is being developed as a potential preventative therapy for cytokine release syndrome (CRS), a serious side effect triggered by cancer immunotherapy treatments.
proactiveinvestors.co.uk
May 11
Poolbeg Pharma secures Canadian patent for cancer immunotherapy drug POLB 001
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received a Canadian patent approval covering the use of its POLB 001 drug candidate in preventing cancer immunotherapy-induced cytokine release syndrome (CRS), a potentially life-threatening immune overreaction triggered by certain cancer treatments. The grant is the second national approval within Poolbeg's CRS patent family, following a ruling by IP Australia in March 2026.
seekingalpha.com
May 1
Poolbeg Pharma PLC (POLBF) Q4 2025 Earnings Call Transcript
Poolbeg Pharma PLC (POLBF) Q4 2025 Earnings Call Transcript
proactiveinvestors.co.uk
Apr 28
Poolbeg eyes transformative summer with POLB 001 data in prospect
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, is heading into its most consequential period since flotation, as interim data from its lead drug candidate POLB 001 approaches and a second trial prepares to start. POLB 001 is designed as an oral preventative therapy for cytokine release syndrome (CRS), a potentially life-threatening inflammatory reaction that affects more than 70% of patients receiving CAR T-cell and bispecific antibody cancer treatments.
